3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
6
Neoplasms
4
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Radiation Injuries
2
Osteosarcoma
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Cognitive Dysfunction
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thoracic Neoplasms
1
Testicular Neoplasms
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Interventions
Sunitinib
17
Sorafenib
16
pazopanib
7
cabozantinib
7
Axitinib
7
Blood Specimen Collection
6
Bevacizumab
6
avelumab
5
Immunohistochemistry
5
temsirolimus
4
pembrolizumab
3
Watchful Waiting
3
Specimen Handling
3
Immunotherapy
3
Gene Expression Profiling
3
Everolimus
3
Urine Specimen Collection
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Flow Cytometry
2
Data Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
lenvatinib
1
fluoroazomycin arabinoside
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Renal Cell
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled